GC/MSD, GC/MS/MS, GC/QQQ
IndustriesPharma & Biopharma
ManufacturerShimadzu
Importance of the Topic
Residual genotoxic impurities, particularly alkyl sulfonate esters such as methyl ethane sulfonate (MES) and ethyl ethane sulfonate (EES), are potent DNA-alkylating agents that can cause mutagenic effects in biological systems.
These impurities may form as by-products during pharmaceutical manufacturing, so sensitive analytical control is essential to meet regulatory safety thresholds and protect patient health.
Objectives and Study Overview
This study aimed to establish a robust GC-MS/MS method for trace-level detection and quantification of MES and EES in an API matrix.
The work focused on optimizing selective multiple reaction monitoring (MRM) transitions and achieving limits of quantification compatible with the 1.5 µg/day mutagenic intake limit.
Methodology and Instrumentation
Sample preparation involved:
- Preparation of a combined MES/EES stock solution (5000 ppb in ethyl acetate).
- Calibration standards at 1–100 ppb in iso-octane.
- Extraction of 75 mg Nintedanib esylate API with 1.5 mL iso-octane followed by filtration.
- Spike recovery studies at 2.5–50 ppb levels.
Chromatographic conditions were set on a 30 m Rtx-1701 column with split injection (5:1), helium carrier, and a temperature program from 70 °C to 260 °C over 25 min.
Mass spectrometry employed electron ionization and Smart MRM optimization to select precursor/product ion pairs and collision energies automatically.
Used Instrumentation
Shimadzu GCMS-TQ8050 triple quadrupole GC-MS/MS system with OFF-AXIS ion optics and high-sensitivity detector, turbo-molecular pump, and LabSolutions Insight software.
Main Results and Discussion
The method achieved:
- Linearity (2.5–100 ppb) with r² values of 0.9998 for MES and 0.9996 for EES.
- Limit of quantification of 2.5 ppb and limit of detection of 1.0 ppb for both analytes.
- Precision at LOQ with RSD ≤ 7.5% (n=6).
- Recoveries between 70% and 130% across spiked levels, demonstrating accuracy and reproducibility.
The optimized Smart MRM workflow reduced method development time by automating transition selection and dwell time optimization.
Benefits and Practical Applications
• Provides a rapid, selective, and high-throughput approach for PGI screening and quantification in pharmaceutical APIs.
• Meets stringent regulatory requirements for genotoxic impurity control.
• Enhances laboratory efficiency through automated MRM optimization.
Future Trends and Opportunities
• Integration of enhanced data analytics and machine learning for predictive impurity profiling.
• Extension of the method to other classes of genotoxic impurities and complex matrices.
• Adoption of miniaturized and high-resolution MS platforms for even lower detection limits.
• Development of universal PGI screening libraries to accelerate method deployment across the industry.
Conclusion
A sensitive, accurate, and reproducible GC-MS/MS method for MES and EES was successfully developed using the Shimadzu GCMS-TQ8050.
The approach aligns with regulatory mutagenic intake thresholds and offers a streamlined workflow for routine impurity monitoring.
Reference
[1] Eldera DP, Snodin DJ. Drug substances presented as sulfonic acid salts: Overview of utility, safety and regulation. J Pharm Pharmacol. 2009;61:269–278.
[2] EMEA/CHMP/QWP/251344/2006.
[3] ICH M7 Guidance. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals. 2015.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.